Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation

2016 ◽  
Vol 64 (2) ◽  
pp. 234-241 ◽  
Author(s):  
Meng-Ju Li ◽  
Hsi-Che Liu ◽  
Hsiu-Ju Yen ◽  
Tang-Her Jaing ◽  
Dong-Tsamn Lin ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Acute Lymphoblastic Leukemia ◽  
Pediatric Oncology ◽  
Lymphoblastic Leukemia ◽  
Preventive Therapy ◽  
Childhood Acute Lymphoblastic Leukemia ◽  
Oncology Group ◽  
Cranial Radiation ◽  
Pediatric Oncology Group

Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study.

1993 ◽  
Vol 11 (2) ◽  
pp. 271-278 ◽  
Author(s):  
N J Winick ◽  
S D Smith ◽  
J Shuster ◽  
S Lauer ◽  
M D Wharam ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Pediatric Oncology ◽  
Lymphoblastic Leukemia ◽  
Treatment Protocol ◽  
Intrathecal Therapy ◽  
Oncology Group ◽  
Treatment Comparison ◽  
Cns Relapse ◽  
Cranial Radiation ◽  
Pediatric Oncology Group

PURPOSE To assess the efficacy and toxicity of chemotherapy and cranial radiation for the treatment of children with acute lymphoblastic leukemia (ALL) following first isolated CNS relapse. PATIENTS AND METHODS One hundred twenty children were treated on Pediatric Oncology Group (POG) protocol 8304. All children had received prophylactic CNS therapy during their initial treatment. The treatment protocol included a four-drug reinduction and six weekly doses of triple intrathecal therapy (TIT). Cranial radiation, 24 Gy, was followed by monthly TIT. Systemic consolidation and maintenance therapy included 6-week cycles of mercaptopurine/methotrexate (6MP/MTX) and vincristine/cyclophosphamide (VCR/CTX), with randomization to intervening pulses of prednisone/doxorubicin (PDN/DOX) or teniposide (VM26)/cytarabine (Ara-C) for a total of 88 weeks. RESULTS All 120 patients achieved a second complete remission. There have been 61 protocol failures. Thirty-five patients had a bone marrow relapse, four with simultaneous CNS involvement and one with concurrent testicular leukemia. Thirteen patients had a second isolated CNS relapse, 10 a testicular relapse, and two relapsed in other sites. One patient died in remission. Overall event-free survival (EFS) at 4 years was 46% +/- 7%. The toxicity associated with this protocol was minimal except for leukoencephalopathy, which occurred in 20 (17%) patients. The treatment comparison between VM26/Ara-C or PDN/DOX pulses showed a trend toward superior EFS (P = .12) in favor of VM-26/Ara-C. CONCLUSION To date, this represents the largest series of patients with ALL treated uniformly for an isolated CNS relapse. Since marrow relapse remains the primary site of failure, future protocols must intensify systemic therapy.

Late effects in survivors of childhood acute lymphoblastic leukemia: a study from Thai Pediatric Oncology Group

2010 ◽  
Vol 91 (5) ◽  
pp. 850-854 ◽  
Author(s):  
Samart Pakakasama ◽  
Gavivann Veerakul ◽  
Darin Sosothikul ◽  
Su-on Chainansamit ◽  
Vichai Laosombat ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Pediatric Oncology ◽  
Late Effects ◽  
Lymphoblastic Leukemia ◽  
Childhood Acute Lymphoblastic Leukemia ◽  
Oncology Group ◽  
Pediatric Oncology Group
Sign in / Sign up

Export Citation Format

Share Document